We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
(-28%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-25.42%
Top 10 Holdings %
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$11.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$8.51M |
| 3 |
United Therapeutics
UTHR
|
+$8.13M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$5.75M |
| 5 |
Altimmune
ALT
|
+$5.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$21M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$9.33M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$8.38M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$7.11M |
| 5 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$6.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.2% |
| 2 | Technology | 0.14% |
| 3 | Consumer Staples | 0.03% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Insmed
INSM
$22.4B
| $2.46M | 0.45% |
+125,000
| New | +$2.62M |
|
52
Viking Therapeutics
VKTX
$3.88B
| $2.41M | 0.44% |
835,275
+302,846
| +57% | +$749K |
|
|
LONA
53
CALL
LeonaBio Inc
LONA
$66.1M
| $2.39M | 0.44% |
78,420
| – | – |
|
|
ISEE
54
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.35M | 0.43% |
+244,400
| New | +$3.07M |
|
55
Cogent Biosciences
COGT
$6.76B
| $2.26M | 0.41% |
+250,000
| New | +$1.71M |
|
56
Adicet Bio
ACET
$77.6M
| $2.09M | 0.38% |
8,951
-22,758
| -72% | -$5M |
|
|
ITOS
57
CALL
DELISTED
iTeos Therapeutics
ITOS
| $2.06M | 0.38% |
+100,000
| New | +$2.37M |
|
|
LYRA
58
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $1.96M | 0.36% |
6,947
-1,500
| -18% | -$408K |
|
|
APLS
59
DELISTED
Apellis Pharmaceuticals
APLS
| $1.89M | 0.35% |
+41,900
| New | +$1.91M |
|
60
Sarepta Therapeutics
SRPT
$1.64B
| $1.87M | 0.34% |
+25,000
| New | +$1.84M |
|
61
Seres Therapeutics
MCRB
$45M
| $1.85M | 0.34% |
27,031
-15,000
| -36% | -$1.29M |
|
62
CALL
BridgeBio Pharma
BBIO
$16.4B
| $1.82M | 0.33% |
+200,000
| New | +$1.67M |
|
|
ATXS
63
DELISTED
Astria Therapeutics
ATXS
| $1.78M | 0.32% |
592,123
+499,900
| +542% | +$2.24M |
|
|
TERN
64
DELISTED
Terns Pharmaceuticals
TERN
| $1.74M | 0.32% |
+700,000
| New | +$1.4M |
|
65
X4 Pharmaceuticals
XFOR
$377M
| $1.62M | 0.3% |
55,992
+10,258
| +22% | +$390K |
|
66
Aldeyra Therapeutics
ALDX
$97.1M
| $1.5M | 0.27% |
375,000
| – | – |
|
|
ICPT
67
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.45M | 0.26% |
105,000
+69,851
| +199% | +$1.12M |
|
|
DBVT
68
DBV Technologies
DBVT
$813M
| $1.4M | 0.26% |
31,694
| – | – |
|
69
Immatics
IMTX
$1.23B
| $1.37M | 0.25% |
157,190
-624,198
| -80% | -$4.94M |
|
|
NTBL
70
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
| $1.34M | 0.24% |
23,714
-22
| -0.1% | -$1.2K |
|
|
WHWK
71
Whitehawk Therapeutics
WHWK
$181M
| $1.27M | 0.23% |
412,343
+203,975
| +98% | +$3.03M |
|
72
PUT
Arcus Biosciences
RCUS
$3.33B
| $1.27M | 0.23% |
+50,000
| New | +$1.22M |
|
73
CALL
Milestone Pharmaceuticals
MIST
$129M
| $1.26M | 0.23% |
+212,400
| New | +$1.31M |
|
|
MRUS
74
DELISTED
Merus
MRUS
| $1.22M | 0.22% |
53,703
| – | – |
|
75
Cabaletta Bio
CABA
$427M
| $1M | 0.18% |
944,431
-75,639
| -7% | -$107K |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.
- Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
- Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
- Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
- Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
- Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
- Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
- Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.
Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.